Zemplar approved for CKD stage 5

[okarol]

Zemplar approved for CKD stage 5
7/30/2009 11:01:16 AM

Abbott Laboratories announced that Zemplar (paricalcitol) capsules are now approved to prevent and treat secondary hyperparathyroidism (SHPT) in stage 5 chronic kidney disease patients who are undergoing peritoneal dialysis or hemodialysis. With this additional approval, Zemplar Capsules are indicated to prevent and treat SHPT associated with CKD stages 3 and 4, and CKD stage 5 patients on hemodialysis or peritoneal dialysis.  To minimize the risk of hypercalcemia, Zemplar capsules should only be initiated in patients with SHPT associated with  CKD stage 5, after their baseline serum calcium has been adjusted to 9.5 mg/dL or lower.1  For full prescribing information on Zemplar visit www.rxabbott.com

http://www.nephronline.com/news.asp?N_ID=3036